Pernix Therapeutics (PTX) Tops Q4 EPS by 7c

Pernix Therapeutics (NASDAQ: PTX) reported Q4 EPS of $0.25, $0.07 better than the analyst estimate of $0.18. Revenue for the quarter came in at $53 million versus the consensus estimate of $52.7 million.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Data I/o Corp (DAIO) Misses Q2 EPS by 7c
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance